Abbott Laboratories (NYSE: ABT) announced the acquisition of Exact Sciences for $21 billion, marking the largest healthcare deal in two years and the largest diagnostic acquisition ever. The deal is expected to complement Abbott’s diagnostic business and was made possible under the Trump administration. Abbott Labs develops healthcare products, including generic medicines, diagnostic systems, nutrition brands, cardiovascular and diabetes care devices, and neuromodulation technologies. While ABT is a strong investment, some AI stocks may offer greater upside potential. For more information on undervalued AI stocks, check out our free report.

Read more at Yahoo Finance: “I Think It’s a Terrific Time to Do Some Buying”